{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:55:40Z","timestamp":1781650540403,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pneumococcal disease (PD) represents a significant public health concern, impacting healthcare systems across Latin America. Mexico\u2019s National Immunization Program introduced infant vaccination with the 7\u2011valent pneumococcal conjugate vaccine (PCV7) in 2008, switching to the 13\u2011valent pneumococcal conjugate vaccine (PCV13) in 2011. Adult vaccination has been included since 2004. Data on Mexico\u2019s disease burden remain limited; therefore, this study aimed to estimate the burden of clinical syndromes associated with pneumococcal disease in 2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis using Mexican administrative hospitalization and mortality databases. Clinical syndromes\u2014including pneumonia, bacteremia, meningitis, and other invasive diseases\u2014were identified using International Classification of Diseases, Tenth Edition (ICD-10) codes. For each syndrome, hospitalization rates, case fatality rates (CFR), and mortality rates were calculated by age group (&lt;\u20091, 1\u20134, 5\u201317, 18\u201349, 50\u201359, and \u2265\u200960 years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 2019, 119,628 hospitalizations related to these syndromes were reported, with pneumonia accounting for 78% of cases. Hospitalization rates were highest among infants aged\u2009&lt;\u20091 year, at 557 per 100,000. CFRs increased with age, reaching 27.8% for pneumonia and 70.9% for bacteremia in adults aged\u2009\u2265\u200960 years. Mortality rates were highest for pneumonia in older adults (156.3 per 100,000) and infants aged\u2009&lt;\u20091 year (45.2 per 100,000).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings highlight the persistent burden of clinical syndromes associated with PD in Mexico despite vaccination efforts, emphasizing the need for improved immunization strategies, particularly among older adults, and strengthened surveillance to inform public health policies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-13297-4","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T08:55:42Z","timestamp":1776416142000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Burden of clinical syndromes associated with pneumococcal disease in Mexico: a retrospective analysis for 2019"],"prefix":"10.1186","volume":"26","author":[{"given":"Juan","family":"Urrego-Reyes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Cornejo-Ju\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica Lynn","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Pungartnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassia","family":"Veiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thais","family":"das Neves Fraga Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9lica Carreira","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cintia Irene","family":"Parellada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"13297_CR1","unstructured":"Dion CFAJ. Streptococcus pneumoniae. StatPearls [Internet]. StatPearls Publishing. 2023."},{"issue":"6","key":"13297_CR2","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41579-018-0001-8","volume":"16","author":"JN Weiser","year":"2018","unstructured":"Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol. 2018;16(6):355\u201367. https:\/\/doi.org\/10.1038\/s41579-018-0001-8.","journal-title":"Nat Rev Microbiol"},{"key":"13297_CR3","unstructured":"ECDC. Factsheet about pneumococcal disease. https:\/\/www.ecdc.europa.eu\/en\/pneumococcal-disease\/facts"},{"issue":"10369","key":"13297_CR4","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/s0140-6736(22)02185-7","volume":"400","author":"Global mortality associated","year":"2022","unstructured":"Global mortality associated. with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;400(10369):2221\u201348. https:\/\/doi.org\/10.1016\/s0140-6736(22)02185-7.","journal-title":"Lancet"},{"issue":"10325","key":"13297_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/s0140-6736(21)02724-0","volume":"12","author":"Antimicrobial Resistance Collaborators","year":"2022","unstructured":"Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet Feb. 2022;12(10325):629\u201355. https:\/\/doi.org\/10.1016\/s0140-6736(21)02724-0.","journal-title":"Lancet Feb"},{"key":"13297_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijid.2017.02.005","volume":"58","author":"MN Carnalla-Barajas","year":"2017","unstructured":"Carnalla-Barajas MN, Soto-Noguer\u00f3n A, S\u00e1nchez-Alem\u00e1n MA, Sol\u00f3rzano-Santos F, Velazquez-Meza ME, Ech\u00e1niz-Aviles G. Changing trends in serotypes of S. pneumoniae isolates causing invasive and non-invasive diseases in unvaccinated population in Mexico (2000\u20132014). Int J Infect Dis. 2017;58:1\u20137. https:\/\/doi.org\/10.1016\/j.ijid.2017.02.005.","journal-title":"Int J Infect Dis"},{"key":"13297_CR7","doi-asserted-by":"publisher","first-page":"127031","DOI":"10.1016\/j.vaccine.2025.127031","volume":"10","author":"A Soto-Noguer\u00f3n","year":"2025","unstructured":"Soto-Noguer\u00f3n A, Carnalla-Barajas MN, S\u00e1nchez-Gonz\u00e1lez G, et al. Distribution of pneumococcal serotypes causing invasive and non-invasive diseases in children in Mexico after introduction of PCV13 (2012\u20132023). Results from the GIVEBPVac group. Vaccine May. 2025;10:55:127031. https:\/\/doi.org\/10.1016\/j.vaccine.2025.127031.","journal-title":"Vaccine May"},{"issue":"2","key":"13297_CR8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.arcmed.2012.12.005","volume":"44","author":"A Bautista-Marquez","year":"2013","unstructured":"Bautista-Marquez A, Richardson V, Ortiz-Orozco O, et al. Prevalence of pneumococcal disease, serotype distribution, and antimicrobial susceptibility in Mexican children younger than 5 years of age. Arch Med Res Feb. 2013;44(2):142\u201350. https:\/\/doi.org\/10.1016\/j.arcmed.2012.12.005.","journal-title":"Arch Med Res Feb"},{"key":"13297_CR9","unstructured":"Gobierno de M\u00e9xico. Programa de Acci\u00f3n Espec\u00edfico: Vacunaci\u00f3n Universal. Accessed 7th November 2025. https:\/\/www.gob.mx\/cms\/uploads\/attachment\/file\/314997\/PAE_Vacunaci_n_Universal.pdf."},{"key":"13297_CR10","unstructured":"Gobierno de M\u00e9xico. Lineamientos generales del Programa de Vacunaci\u00f3n Universal y Semanas Nacionales de Salud 2019. Accessed 7th. November 2025. https:\/\/www.gob.mx\/cms\/uploads\/attachment\/file\/416064\/Lineamientos_Generales_PVU_y_SNS_2019.pdf"},{"key":"13297_CR11","unstructured":"Mexico GD. Actualizaci\u00f3n del esquema de vacunaci\u00f3n para la prevenci\u00f3n de neumon\u00eda por neumococo. Gobierno De Mexico. https:\/\/www.gob.mx\/salud\/censia\/es\/articulos\/actualizacion-del-esquema-de-vacunacion-para-la-prevencion-de-neumonia-por-neumococo-322570?idiom=es"},{"key":"13297_CR12","unstructured":"Gobierno de M\u00e9xico. Salud PRONAM Vacunaci\u00f3n a lo largo de la vida. 2025. https:\/\/pronamsalud.csg.gob.mx\/pronam-vacunacion-a-lo-largo-de-la-vida.pdf"},{"key":"13297_CR13","unstructured":"Secretar\u00eda de Salud. Programa de vacunaci\u00f3n universal Lineamientos Generales 2025. Accessed 26th. February 2026. https:\/\/www.gob.mx\/cms\/uploads\/attachment\/file\/977163\/Lineamientos_Generales_2025_.pdf"},{"key":"13297_CR14","doi-asserted-by":"publisher","unstructured":"Mongua-Rodr\u00edguez N, Delgado-S\u00e1nchez G, Ferreira-Guerrero E, et al. Cobertura de vacunaci\u00f3n en ni\u00f1os, ni\u00f1as y adolescentes en M\u00e9xico. Salud Publica Mex. Jun 15. 2023;65:s23-s33. https:\/\/doi.org\/10.21149\/14790","DOI":"10.21149\/14790"},{"key":"13297_CR15","doi-asserted-by":"publisher","unstructured":"Mongua-Rodr\u00edguez N, Ferreira-Guerrero E, Delgado-S\u00e1nchez G, et al. Vacunaci\u00f3n en adultos y adultos mayores en M\u00e9xico. Salud Publica Mex. Jun 13. 2023;65:s146-s152. https:\/\/doi.org\/10.21149\/14786","DOI":"10.21149\/14786"},{"issue":"11","key":"13297_CR16","doi-asserted-by":"publisher","first-page":"4667","DOI":"10.1080\/21645515.2021.1972709","volume":"2","author":"J Nieto Guevara","year":"2021","unstructured":"Nieto Guevara J, Guzman-Holst A. Laboratory-based surveillance in Latin America: attributes and limitations in evaluation of pneumococcal vaccine impact. Hum Vaccin Immunother Nov. 2021;2(11):4667\u201372. https:\/\/doi.org\/10.1080\/21645515.2021.1972709.","journal-title":"Hum Vaccin Immunother Nov"},{"key":"13297_CR17","unstructured":"Trejo-Valdivia B, Mendoza-Alvarado L, Palma-Coca O, Hern\u00e1ndez-\u00c1vila M, T\u00e9llez-Rojo Sol\u00eds MM. Encuesta Nacional de Cobertura de Vacunaci\u00f3n (influenza, neumococo y t\u00e9tanos) en Adultos Mayores de 60 a\u00f1os en M\u00e9xico. Accessed 26th 2026. https:\/\/www.redalyc.org\/pdf\/106\/10623032006.pdf"},{"key":"13297_CR18","unstructured":"Gobierno de M\u00e9xico. Grupo Interinstitucional para la Vigilancia de Enfermedades Bacterianas Prevenibles por Vacunaci\u00f3n (GIVEBPVac). Updated 19th November 2024. Accessed 15th. July 2025. https:\/\/www.insp.mx\/lineas-de-investigacion\/medicamentos-en-salud-publica\/sireva.html"},{"issue":"1","key":"13297_CR19","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1186\/s12889-025-23631-1","volume":"1","author":"CI Parellada","year":"2025","unstructured":"Parellada CI, Reyes LF, Urrego-Reyes J, et al. Assessing the impact of childhood pneumococcal vaccination on pneumonia mortality in Colombia: a 14-year analysis. BMC Public Health Sep. 2025;1(1):2990. https:\/\/doi.org\/10.1186\/s12889-025-23631-1.","journal-title":"BMC Public Health Sep"},{"key":"13297_CR20","unstructured":"Programa Presupuestario IMSS-BIENESTAR. E001: Atenci\u00f3n a la Salud de Personas Sin Seguridad Social. 2024. April 12. https:\/\/www.imssbienestar.gob.mx\/assets\/docs\/apertura_gubernamental\/programas\/240618_DIAGNOST_PP_E001_24.pdf"},{"key":"13297_CR21","unstructured":"National Institute of Statistics and Geography. Poblaci\u00f3n con afiliaci\u00f3n a servicios de salud por entidad federativa seg\u00fan instituci\u00f3n. 2020. Accessed 7th November 2025. https:\/\/www.inegi.org.mx\/app\/tabulados\/interactivos\/?pxq=Derechohabiencia_Derechohabiencia_02_822ebcc5-ef41-40c1-9901-22e397025c64&idrt=143&opc=t"},{"issue":"4","key":"13297_CR22","doi-asserted-by":"publisher","first-page":"e0153141","DOI":"10.1371\/journal.pone.0153141","volume":"11","author":"J Diaz","year":"2016","unstructured":"Diaz J, Terrazas S, Bierrenbach AL, et al. Effectiveness of the 10-Valent Pneumococcal Conjugate Vaccine (PCV-10) in Children in Chile: A Nested Case-Control Study Using Nationwide Pneumonia Morbidity and Mortality Surveillance Data. PLoS ONE. 2016;11(4):e0153141. https:\/\/doi.org\/10.1371\/journal.pone.0153141.","journal-title":"PLoS ONE"},{"issue":"2","key":"13297_CR23","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/cid\/ciaa614","volume":"15","author":"LH de Oliveira","year":"2021","unstructured":"de Oliveira LH, Shioda K, Valenzuela MT, et al. Declines in Pneumonia Mortality Following the Introduction of Pneumococcal Conjugate Vaccines in Latin American and Caribbean Countries. Clin Infect Dis Jul. 2021;15(2):306\u201313. https:\/\/doi.org\/10.1093\/cid\/ciaa614.","journal-title":"Clin Infect Dis Jul"},{"key":"13297_CR24","unstructured":"Parellada C, Cornejo D, Hirata L, et al. Childhood pneumococcal vaccination and pneumonia mortality rates across all ages in Mexico between 2004\u20132019: a time-series trend analysis. 2025."},{"issue":"4","key":"13297_CR25","doi-asserted-by":"publisher","first-page":"e768","DOI":"10.1093\/infdis\/jiae144","volume":"16","author":"O Prunas","year":"2024","unstructured":"Prunas O, Shioda K, Toscano CM, et al. Estimated Population-Level Impact of Pneumococcal Conjugate Vaccines Against All-Cause Pneumonia Mortality Among Unvaccinated in 5 Latin American Countries. J Infect Dis Oct. 2024;16(4):e768\u201376. https:\/\/doi.org\/10.1093\/infdis\/jiae144.","journal-title":"J Infect Dis Oct"},{"issue":"3","key":"13297_CR26","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/s1473-3099(20)30511-9","volume":"21","author":"CG Whitney","year":"2021","unstructured":"Whitney CG, Toscano CM. Direct effects of pneumococcal conjugate vaccines among children in Latin America and the Caribbean. Lancet Infect Dis Mar. 2021;21(3):306\u20138. https:\/\/doi.org\/10.1016\/s1473-3099(20)30511-9.","journal-title":"Lancet Infect Dis Mar"},{"issue":"7","key":"13297_CR27","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/j.1469-0691.2004.00872.x","volume":"10","author":"M Castanheira","year":"2004","unstructured":"Castanheira M, Gales AC, Mendes RE, Jones RN, Sader HS. Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY Antimicrobial Surveillance Program. Clin Microbiol Infect Jul. 2004;10(7):645\u201351. https:\/\/doi.org\/10.1111\/j.1469-0691.2004.00872.x.","journal-title":"Clin Microbiol Infect Jul"},{"issue":"6","key":"13297_CR28","doi-asserted-by":"publisher","first-page":"e0304978","DOI":"10.1371\/journal.pone.0304978","volume":"19","author":"A Bardach","year":"2024","unstructured":"Bardach A, Ruvinsky S, Palermo MC, et al. Invasive pneumococcal disease in Latin America and the Caribbean: Serotype distribution, disease burden, and impact of vaccination. A systematic review and meta-analysis. PLoS ONE. 2024;19(6):e0304978. https:\/\/doi.org\/10.1371\/journal.pone.0304978.","journal-title":"PLoS ONE"},{"key":"13297_CR29","doi-asserted-by":"publisher","unstructured":"Olesen SW, Barnett ML, MacFadden DR, et al. The distribution of antibiotic use and its association with antibiotic resistance. Elife Dec. 2018;18. https:\/\/doi.org\/10.7554\/eLife.39435.","DOI":"10.7554\/eLife.39435"},{"issue":"4","key":"13297_CR30","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/s1473-3099(24)00665-0","volume":"25","author":"JC Bennett","year":"2025","unstructured":"Bennett JC, Deloria Knoll M, Kagucia EW, et al. Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis. Lancet Infect Dis Apr. 2025;25(4):457\u201370. https:\/\/doi.org\/10.1016\/s1473-3099(24)00665-0.","journal-title":"Lancet Infect Dis Apr"},{"issue":"1","key":"13297_CR31","doi-asserted-by":"publisher","first-page":"ofaf774","DOI":"10.1093\/ofid\/ofaf774","volume":"13","author":"LM King","year":"2026","unstructured":"King LM, Andrejko KL, Kobayashi M, Xing W, Cohen AL, Lewnard JA. Acute Respiratory Infections Due to Antibiotic-nonsusceptible Streptococcus pneumoniae in US Adults. Open Forum Infect Dis Jan. 2026;13(1):ofaf774. https:\/\/doi.org\/10.1093\/ofid\/ofaf774.","journal-title":"Open Forum Infect Dis Jan"},{"key":"13297_CR32","doi-asserted-by":"publisher","first-page":"101684","DOI":"10.1016\/j.ssmph.2024.101684","volume":"26","author":"A Salinas-Rodr\u00edguez","year":"2024","unstructured":"Salinas-Rodr\u00edguez A, Rojas-Botero ML, Rivera-Almaraz A, Fern\u00e1ndez-Ni\u00f1o JA, Monta\u00f1ez-Hern\u00e1ndez JC, Manrique-Espinoza B. Long-term inequalities in health among older Mexican adults: An outcome-wide analysis. SSM Popul Health Jun. 2024;26:101684. https:\/\/doi.org\/10.1016\/j.ssmph.2024.101684.","journal-title":"SSM Popul Health Jun"},{"issue":"5","key":"13297_CR33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/s1473-3099(10)70048-7","volume":"10","author":"K Edmond","year":"2010","unstructured":"Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis May. 2010;10(5):317\u201328. https:\/\/doi.org\/10.1016\/s1473-3099(10)70048-7.","journal-title":"Lancet Infect Dis May"},{"key":"13297_CR34","doi-asserted-by":"publisher","unstructured":"Hooven TA, Polin RA. Pneumonia. Semin Fetal Neonatal Med. 2017;22(4):206\u201313. https:\/\/doi.org\/10.1016\/j.siny.2017.03.002","DOI":"10.1016\/j.siny.2017.03.002"},{"issue":"12","key":"13297_CR35","doi-asserted-by":"publisher","first-page":"ofad580","DOI":"10.1093\/ofid\/ofad580","volume":"10","author":"J Kubale","year":"2023","unstructured":"Kubale J, Kujawski S, Chen I, et al. Etiology of Acute Lower Respiratory Illness Hospitalizations Among Infants in 4 Countries. Open Forum Infect Dis Dec. 2023;10(12):ofad580. https:\/\/doi.org\/10.1093\/ofid\/ofad580.","journal-title":"Open Forum Infect Dis Dec"},{"key":"13297_CR36","doi-asserted-by":"publisher","unstructured":"Duke T. Neonatal pneumonia in developing countries. Arch Dis Child Fetal Neonatal Ed. 2005;90(3):F211\u20139. https:\/\/doi.org\/10.1136\/adc.2003.048108","DOI":"10.1136\/adc.2003.048108"},{"issue":"7","key":"13297_CR37","doi-asserted-by":"publisher","first-page":"e70135","DOI":"10.1111\/irv.70135","volume":"19","author":"N Wolter","year":"2025","unstructured":"Wolter N, Cohen C, von Gottberg A, et al. Aetiological Fraction of Influenza, Respiratory Syncytial Virus and Other Respiratory Pathogens in Infants Aged\u2009<\u20091 Year Hospitalised With Respiratory and Non-Respiratory Medical Illness in South Africa, 2016\u20132018. Influenza Other Respir Viruses Jul. 2025;19(7):e70135. https:\/\/doi.org\/10.1111\/irv.70135.","journal-title":"Influenza Other Respir Viruses Jul"},{"key":"13297_CR38","unstructured":"World Health Organisation. WHO methods and data sources for country-level causes of death 2000\u20132019. 2020. https:\/\/www.who.int\/docs\/default-source\/gho-documents\/global-health-estimates\/ghe2019_cod_methods.pdf"},{"issue":"9","key":"13297_CR39","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/s1473-3099(24)00176-2","volume":"24","author":"GBD 2021 Lower Respiratory Infections and Antimicrobial Resistance Collaborators","year":"2024","unstructured":"GBD 2021 Lower Respiratory Infections and Antimicrobial Resistance Collaborators. Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990\u20132021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Infect Dis Sep. 2024;24(9):974\u20131002. https:\/\/doi.org\/10.1016\/s1473-3099(24)00176-2.","journal-title":"Lancet Infect Dis Sep"},{"issue":"3","key":"13297_CR40","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1378\/chest.06-1800","volume":"131","author":"A D\u00edaz","year":"2007","unstructured":"D\u00edaz A, Barria P, Niederman M, et al. Etiology of community-acquired pneumonia in hospitalized patients in chile: the increasing prevalence of respiratory viruses among classic pathogens. Chest Mar. 2007;131(3):779\u201387. https:\/\/doi.org\/10.1378\/chest.06-1800.","journal-title":"Chest Mar"},{"key":"13297_CR41","unstructured":"Mora Mora LA, Arco Espinosa ME, Plumet J, Micheli F. [Community acquired bacterial meningitis in patients over 60]. Meningitis bacteriana adquirida en la comunidad en mayores de 60 a\u00f1os. Medicina (B Aires). 2015;75(6):367-72."},{"key":"13297_CR42","doi-asserted-by":"publisher","unstructured":"Parellada CI, Abreu AJL, Birck MG, et al. Trends in pneumococcal and bacterial meningitis in Brazil from 2007 to 2019. Vaccines (Basel). Jul. 2023;25(8). https:\/\/doi.org\/10.3390\/vaccines11081279.","DOI":"10.3390\/vaccines11081279"},{"issue":"2","key":"13297_CR43","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1017\/s0950268807008564","volume":"136","author":"SA Skull","year":"2008","unstructured":"Skull SA, Andrews RM, Byrnes GB, et al. ICD-10 codes are a valid tool for identification of pneumonia in hospitalized patients aged\u2009>\u2009or =\u200965 years. Epidemiol Infect Feb. 2008;136(2):232\u201340. https:\/\/doi.org\/10.1017\/s0950268807008564.","journal-title":"Epidemiol Infect Feb"},{"issue":"3","key":"13297_CR44","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/oxfordjournals.aje.a009804","volume":"1","author":"RE Guevara","year":"1999","unstructured":"Guevara RE, Butler JC, Marston BJ, Plouffe JF, File TM Jr., Breiman RF. Accuracy of ICD-9-CM codes in detecting community-acquired pneumococcal pneumonia for incidence and vaccine efficacy studies. Am J Epidemiol Feb. 1999;1(3):282\u20139. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a009804.","journal-title":"Am J Epidemiol Feb"},{"key":"13297_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/s0950268822000607","volume":"4","author":"TM Lyngstad","year":"2022","unstructured":"Lyngstad TM, Kristoffersen AB, Winje BA, Steens A. Estimation of the incidence of hospitalization for non-invasive pneumococcal pneumonia in the Norwegian population aged 50 years and older. Epidemiol Infect Apr. 2022;4:150:1\u201321. https:\/\/doi.org\/10.1017\/s0950268822000607.","journal-title":"Epidemiol Infect Apr"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13297-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13297-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13297-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:16:57Z","timestamp":1781648217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13297-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13297"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13297-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by the Instituto Nacional de Cancerolog\u00eda (INCAN) ethics committee (INCAN\/CEI\/690\/21 on July 08, 2021), in accordance with the local regulation. It was also registered in COFEPRIS under number 12 CEI 0901411 and CONBIOETICA-09-CEI-002-20160413. Informed consent was not applicable as all data was extracted from publicly available and structured databases containing anonymized and aggregated data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare the following financial interests\/personal relationships which may be considered as potential competing interest: JUR is an employee of MSD Colombia, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, who may own stock and\/or hold stock options in Merck & Co., Inc., Rahway, NJ, USA. PP, CV, TNMF and CIP are employees of MSD Brazil, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, who may own stock and\/or hold stock options in Merck & Co., Inc., Rahway, NJ, USA. JW was employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA by the time of the study. ACDS is an employee of IQVIA Brazil. PCJ has received honoraria for presentations, educational events, consulting, and investigational grants from Stendhal, Pfizer, MSD, Knight-Biotoscana, Liomont, and Lilly.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1122"}}